---
layout: default
title: Pravastatin
description: "Pravastatin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 9 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 137
evidence_level: L1
indication_count: 9
---

# Pravastatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>9</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pravastatin (æ™®ä¼ä»–æ±€) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pravastatin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
æ™®ä¼ä»–æ±€æ˜¯ä¸€ç¨®HMG-CoAé‚„åŸé…¶æŠ‘åˆ¶åŠ‘(ä»–æ±€é¡è—¥ç‰©),TxGNNé æ¸¬å…¶å¯ç”¨æ–¼åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡å’ŒHIVæ„ŸæŸ“ç›¸é—œè¡€è„‚ç•°å¸¸,å…©è€…å‡æœ‰è‡¨åºŠè©¦é©—å’Œæ–‡ç»è­‰æ“šæ”¯æŒ,ä¸”éƒ¨åˆ†å·²æ¥è¿‘æ ¸å‡†é©æ‡‰ç—‡ç¯„åœã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Pravastatin (æ™®ä¼ä»–æ±€) |
| DrugBank ID | DB00175 |
| å°ç£å“ç‰Œå | å¸•ç“¦æ–¯å¾·å®šéˆ‰é¹½ã€Mevalotinç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é«˜è¡€è„‚ç—‡ã€å¿ƒè¡€ç®¡ç–¾ç—…é é˜²ã€ç§»æ¤å¾Œé«˜è„‚è¡€ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | homozygous familial hypercholesterolemiaã€obsolete familial combined hyperlipidemiaã€HIV infectious diseaseã€neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matterã€feline acquired immunodeficiency syndromeã€simian immunodeficiency virus infectionã€hyperlipoproteinemiaã€familial hypercholesterolemiaã€hypoalphalipoproteinemia |
| æœ€é«˜è­‰æ“šç­‰ç´š | L1-L2 (å¤šå€‹RCTæ”¯æŒ) |
| è‡¨åºŠè©¦é©—æ•¸ | 4é …ä»¥ä¸Š |
| æ–‡ç»æ”¯æŒ | è±å¯Œ (>13ç¯‡) |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. homozygous familial hypercholesterolemia</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.95%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>### åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡é æ¸¬åˆ†æ (TxGNN Score: 0.9995, Rank: 1691)</p>

<ol>
<li><strong>ä»–æ±€é¡è—¥ç‰©æ©Ÿåˆ¶</strong>: PravastatinæŠ‘åˆ¶HMG-CoAé‚„åŸé…¶,æ¸›å°‘è‚è‡Ÿè†½å›ºé†‡åˆæˆ</li>
<li><strong>å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡æ²»ç™‚</strong>: å·²æ ¸å‡†ç”¨æ–¼å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡(heterozygous)</li>
<li><strong>åŒåˆå­å‹æŒ‘æˆ°</strong>: hoFHæ‚£è€…LDLå—é«”åŠŸèƒ½åš´é‡ç¼ºé™·,å–®ä¸€ä»–æ±€ç™‚æ•ˆæœ‰é™ä½†ä»ç‚ºåŸºç¤æ²»ç™‚</li>
<li><strong>åˆä½µæ²»ç™‚ç­–ç•¥</strong>: é€šå¸¸éœ€èˆ‡PCSK9æŠ‘åˆ¶åŠ‘ã€ezetimibeã€LDLè¡€æ¼¿åˆ†é›¢è¡“åˆä½µ</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ç›¸é—œè©¦é©—</p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>Phase</th>
<th>ç‹€æ…‹</th>
<th>ç ”ç©¶è—¥ç‰©</th>
<th>èªªæ˜</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03510715</td>
<td>Phase 3</td>
<td>å·²å®Œæˆ</td>
<td>Alirocumab</td>
<td>å…’ç«¥é’å°‘å¹´hoFH,èƒŒæ™¯ä»–æ±€æ²»ç™‚</td>
</tr>
</tbody>
</table>

<p><strong>NCT03510715è©¦é©—é‡é»</strong>:</p>
<ul>
<li>8-17æ­²hoFHæ‚£è€…</li>
<li>åœ¨ä»–æ±€é¡(å«pravastatin)+/-å…¶ä»–é™è„‚è—¥åŸºç¤ä¸ŠåŠ ç”¨alirocumab</li>
<li>è­‰å¯¦åˆä½µç™‚æ³•çš„å¯è¡Œæ€§</li>
</ul>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ç›¸é—œæ–‡ç» (>13ç¯‡)</p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>ç ”ç©¶é¡å‹</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>28437620</td>
<td>2017</td>
<td>æŒ‡å¼•</td>
<td>AACE/ACEè¡€è„‚ç•°å¸¸ç®¡ç†æŒ‡å¼•</td>
</tr>
<tr>
<td>28685504</td>
<td>2017</td>
<td>Cochraneç³»çµ±æ€§å›é¡§</td>
<td>å…’ç«¥FHçš„ä»–æ±€é¡è—¥ç‰©æ²»ç™‚</td>
</tr>
<tr>
<td>31696945</td>
<td>2019</td>
<td>Cochraneç³»çµ±æ€§å›é¡§æ›´æ–°</td>
<td>ç¢ºèªä»–æ±€åœ¨å…’ç«¥FHçš„è§’è‰²</td>
</tr>
<tr>
<td>12269853</td>
<td>2002</td>
<td>è—¥ç‰©è©•è«–</td>
<td>Rosuvastatinèˆ‡pravastatinæ¯”è¼ƒ</td>
</tr>
</tbody>
</table>

<p><strong>é—œéµç™¼ç¾</strong>:</p>
<ul>
<li>ä»–æ±€é¡è—¥ç‰©æ˜¯å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡çš„åŸºç¤æ²»ç™‚</li>
<li>å…’ç«¥æœŸé–‹å§‹æ²»ç™‚å¯é™ä½é•·æœŸå¿ƒè¡€ç®¡é¢¨éšª</li>
<li>hoFHéœ€å¤šé‡ç™‚æ³•åˆä½µ,å–®ä¸€ä»–æ±€æ•ˆæœæœ‰é™</li>
</ul>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. HIV infectious disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.74%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ16 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00982189" target="_blank">NCT00982189</a></td><td>NA</td><td>COMPLETED</td><td>37</td><td>Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00227500" target="_blank">NCT00227500</a></td><td>PHASE4</td><td>COMPLETED</td><td>40</td><td>A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipida...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00017758" target="_blank">NCT00017758</a></td><td>PHASE1</td><td>COMPLETED</td><td>56</td><td>The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylg...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00039663" target="_blank">NCT00039663</a></td><td>PHASE1</td><td>COMPLETED</td><td>75</td><td>Endothelial Dysfunction as a Risk Factor in HIV Study</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00665717" target="_blank">NCT00665717</a></td><td>PHASE1</td><td>COMPLETED</td><td>24</td><td>The Influence of Raltegravir on Pravastatin Pharmacokinetics in Healthy Voluntee...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 11 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28252528/" target="_blank">28252528</a></td><td>2017</td><td>Article</td><td>AIDS (London, Englan</td><td>Effects of pitavastatin and pravastatin on markers of immune...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28416195/" target="_blank">28416195</a></td><td>2017</td><td>Article</td><td>The lancet. HIV</td><td>Pitavastatin versus pravastatin in adults with HIV-1 infecti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18991624/" target="_blank">18991624</a></td><td>2008</td><td>Article</td><td>Current HIV research</td><td>Rosuvastatin, pravastatin, and atorvastatin for the treatmen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26148680/" target="_blank">26148680</a></td><td>2015</td><td>Article</td><td>BMC research notes</td><td>Effects of pravastatin, phytosterols, and combination therap...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18510890/" target="_blank">18510890</a></td><td>2008</td><td>Article</td><td>Current HIV/AIDS rep</td><td>Pathogenesis and management of lipoatrophy.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.62%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. feline acquired immunodeficiency syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. simian immunodeficiency virus infection</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. familial hypercholesterolemia</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.34%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ6 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03510715" target="_blank">NCT03510715</a></td><td>PHASE3</td><td>COMPLETED</td><td>18</td><td>An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Childre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02107898" target="_blank">NCT02107898</a></td><td>PHASE3</td><td>COMPLETED</td><td>216</td><td>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Stud...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01890967" target="_blank">NCT01890967</a></td><td>PHASE2</td><td>COMPLETED</td><td>527</td><td>A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00688896" target="_blank">NCT00688896</a></td><td>PHASE2</td><td>COMPLETED</td><td>155</td><td>A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Eva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03510884" target="_blank">NCT03510884</a></td><td>PHASE3</td><td>COMPLETED</td><td>153</td><td>A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label T...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 1 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ13 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31618540/" target="_blank">31618540</a></td><td>2019</td><td>Article</td><td>The New England jour</td><td>20-Year Follow-up of Statins in Children with Familial Hyper...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28437620/" target="_blank">28437620</a></td><td>2017</td><td>Article</td><td>Endocrine practice :</td><td>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERIC...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31696945/" target="_blank">31696945</a></td><td>2019</td><td>Article</td><td>The Cochrane databas</td><td>Statins for children with familial hypercholesterolemia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28685504/" target="_blank">28685504</a></td><td>2017</td><td>Article</td><td>The Cochrane databas</td><td>Statins for children with familial hypercholesterolemia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12891228/" target="_blank">12891228</a></td><td>2003</td><td>Article</td><td>Clinical pharmacolog</td><td>Pharmacokinetics and pharmacodynamics of pravastatin in chil...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 8 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hypoalphalipoproteinemia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21107758/" target="_blank">21107758</a></td><td>2011</td><td>Article</td><td>Current atherosclero</td><td>What combination therapy with a statin, if any, would you re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12679198/" target="_blank">12679198</a></td><td>2003</td><td>Article</td><td>The American journal</td><td>High-density lipoprotein subpopulations in pathologic condit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9362407/" target="_blank">9362407</a></td><td>1997</td><td>Article</td><td>Journal of the Ameri</td><td>Modulation of lipoprotein(a) atherogenicity by high density ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. cholesterol-ester transfer protein deficiency</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.04%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11741245/" target="_blank">11741245</a></td><td>2000</td><td>Article</td><td>AAPS pharmSci</td><td>Assessing the cost-effectiveness of pharmacogenomics.</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### æœ‰æ•ˆè¨±å¯è­‰

å°ç£å·²æœ‰å¤šé …pravastatinè£½åŠ‘æ ¸å‡†,æ ¸å‡†é©æ‡‰ç—‡åŒ…æ‹¬:

1. **é«˜è¡€è„‚ç—‡**: åŸç™¼æ€§é«˜è†½å›ºé†‡è¡€ç—‡ã€æ··åˆå‹é«˜è¡€è„‚ç—‡
2. **åˆç™¼æ€§é é˜²**: é«˜è†½å›ºé†‡è¡€ç—‡ç„¡å† å¿ƒç—…æ‚£è€…çš„å¿ƒè‚Œæ¢—å¡é é˜²
3. **å†ç™¼æ€§é é˜²**: å† å¿ƒç—…æ‚£è€…çš„äºŒæ¬¡é é˜²
4. **ç§»æ¤å¾Œé«˜è„‚è¡€ç—‡**: å¿ƒè‡Ÿç§»æ¤å¾Œå…ç–«æŠ‘åˆ¶æ²»ç™‚ç›¸é—œé«˜è„‚è¡€ç—‡

### é‡è¦èªªæ˜
å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡å·²åœ¨éƒ¨åˆ†è£½åŠ‘æ ¸å‡†é©æ‡‰ç—‡ä¸­æåŠã€‚

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥å®‰å…¨æ€§è³‡è¨Š

1. **è‚Œè‚‰æ¯’æ€§**: ç½•è¦‹ä½†å¯èƒ½ç™¼ç”Ÿæ©«ç´‹è‚Œæº¶è§£ç—‡
2. **è‚åŠŸèƒ½ç•°å¸¸**: éœ€ç›£æ¸¬è‚åŠŸèƒ½æŒ‡æ•¸
3. **ç³–å°¿ç—…é¢¨éšª**: é•·æœŸä½¿ç”¨å¯èƒ½è¼•å¾®å¢åŠ ç³–å°¿ç—…é¢¨éšª
4. **è—¥ç‰©äº¤äº’ä½œç”¨**: èˆ‡éƒ¨åˆ†è—¥ç‰©æœ‰äº¤äº’ä½œç”¨,ä½†ç¨‹åº¦è¼ƒå…¶ä»–ä»–æ±€è¼•

### HIVæ‚£è€…ç‰¹æ®Šè€ƒé‡

1. **CYPä»£è¬å„ªå‹¢**: Pravastatinä¸ç¶“CYP3A4ä»£è¬
2. **èˆ‡æŠ—ç—…æ¯’è—¥ç‰©äº¤äº’ä½œç”¨**:
   - èˆ‡è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘äº¤äº’ä½œç”¨è¼ƒå°‘
   - Lopinavir/ritonavirå¯èƒ½å¢åŠ pravastatinè¡€ä¸­æ¿ƒåº¦
3. **ç›£æ¸¬å»ºè­°**: ä»éœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½å’Œè‚Œé…¸æ¿€é…¶

### è—¥ç‰©äº¤äº’ä½œç”¨é‡é»

- èˆ‡fibratesä½µç”¨å¢åŠ è‚Œç—…é¢¨éšª
- èˆ‡å…ç–«æŠ‘åˆ¶åŠ‘(ciclosporin)äº¤äº’éœ€è¬¹æ…
- èˆ‡æŠ—å‡è¡€åŠ‘éœ€ç›£æ¸¬INR


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Cognitive Dysfunction** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦é™ä½åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**Rhabdomyolysis** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°

| è©•ä¼°é …ç›® | åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ | HIVç›¸é—œè¡€è„‚ç•°å¸¸ |
|----------|--------------------------|------------------|
| è­‰æ“šç­‰ç´š | L2 (ç³»çµ±æ€§å›é¡§æ”¯æŒ) | L1-L2 (å¤šå€‹RCT) |
| æ©Ÿåˆ¶åˆç†æ€§ | é«˜ (å·²ç‚ºåŸºç¤æ²»ç™‚) | é«˜ (ä»£è¬å„ªå‹¢) |
| è‡¨åºŠå¯è¡Œæ€§ | é«˜ (åˆä½µç™‚æ³•ä¸€éƒ¨åˆ†) | é«˜ |
| å»ºè­°å„ªå…ˆé †åº | é«˜ | é«˜ |

### å»ºè­°

**åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡**:
1. **è‡¨åºŠå®šä½**: ä½œç‚ºhoFHå¤šé‡ç™‚æ³•çš„åŸºç¤æ²»ç™‚
2. **åˆä½µç”¨è—¥**: éœ€èˆ‡PCSK9æŠ‘åˆ¶åŠ‘ã€ezetimibeç­‰åˆä½µ
3. **é©æ‡‰ç—‡æ“´å±•**: è€ƒæ…®åœ¨ç¾æœ‰å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡é©æ‡‰ç—‡ä¸‹åŒ…å«hoFH

**HIVç›¸é—œè¡€è„‚ç•°å¸¸**:
1. **é¦–é¸ä»–æ±€ä¹‹ä¸€**: å› ä»£è¬ç‰¹æ€§,ç‚ºHIVæ‚£è€…è¼ƒå®‰å…¨çš„ä»–æ±€é¸æ“‡
2. **è‡¨åºŠæ¨å»£**: å¯åœ¨æŠ—ç—…æ¯’æ²»ç™‚ç›¸é—œè¡€è„‚ç•°å¸¸æŒ‡å¼•ä¸­æ¨è–¦
3. **è—¥å‹•å­¸å„ªå‹¢**: ç‰¹åˆ¥é©ç”¨æ–¼ä½¿ç”¨CYP3A4æŠ‘åˆ¶åŠ‘å‹æŠ—ç—…æ¯’è—¥ç‰©çš„æ‚£è€…

### å¯¦å‹™å»ºè­°

1. **ç›£æ¸¬è¨ˆç•«**:
   - åŸºç·šå’Œæ²»ç™‚æœŸé–“å®šæœŸç›£æ¸¬è‚åŠŸèƒ½ã€CK
   - HIVæ‚£è€…æ³¨æ„ç—…æ¯’è¼‰é‡å’ŒCD4è®ŠåŒ–

2. **åŠ‘é‡è€ƒé‡**:
   - HIVæ‚£è€…å¯èƒ½éœ€è¼ƒä½èµ·å§‹åŠ‘é‡
   - æ ¹æ“šé™è„‚æ•ˆæœèª¿æ•´åŠ‘é‡

### é™åˆ¶èªªæ˜

- hoFHæ‚£è€…å› LDLå—é«”ç¼ºé™·,ä»–æ±€å–®ä¸€ç™‚æ³•æ•ˆæœæœ‰é™
- Pravastatiné™è„‚æ•ˆåŠ›ä¸å¦‚å…¶ä»–é«˜æ•ˆä»–æ±€(å¦‚atorvastatin, rosuvastatin)
- HIVæ‚£è€…çš„å¿ƒè¡€ç®¡é å¾Œé•·æœŸæ•¸æ“šä»åœ¨ç´¯ç©ä¸­

---
*å ±å‘Šç”¢ç”Ÿæ—¥æœŸ: 2026-02-11*
*è³‡æ–™ä¾†æº: TxGNNé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£é£Ÿå“è—¥ç‰©ç®¡ç†ç½²*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nepafenac]({{ "/drugs/nepafenac/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pimozide]({{ "/drugs/pimozide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bempedoic Acid]({{ "/drugs/bempedoic_acid/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pravastatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pravastatin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pravastatin,
  title = {Pravastatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pravastatin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
